Patient-reported health care utilization in rheumatoid arthritis: what level of detail is required?
- PMID: 15478161
- DOI: 10.1002/art.20686
Patient-reported health care utilization in rheumatoid arthritis: what level of detail is required?
Abstract
Objective: To investigate the level of detail required in self-reported health care utilization questionnaires for administration to patients with rheumatoid arthritis (RA).
Methods: A preliminary questionnaire was developed on the basis of existing tools for use in rheumatic conditions and in-depth interviews with 10 RA patients. Data gathered over 1 year of administration in a clinical setting were then matched to a comprehensive database of payer-reported information. Kappa statistics were calculated for each health care utilization domain. For domains where disaggregation into metric data was potentially preferable, histograms of difference were assessed visually and the strength of association examined using Spearman's rank correlation coefficient.
Results: Patients (n = 136) included in the base case analysis determined the preferred levels of detail for each domain. Physician visits: occurrence of physician visits (yes/no; kappa not applicable) and their number (r = 0.42, P < 0.001). Medication use of the following drug classes (yes/no): disease-modifying antirheumatic drug (DMARD; kappa = 0.68), nonsteroidal antiinflammatory drug (kappa = 0.64), osteoporosis medication (kappa = 0.56), analgesic (kappa = 0.38), and steroid (kappa = 0.83). Further disaggregation into different DMARD classes was recommended (kappa ranging between 1 [use of biologics: yes/no] and 0.67 [use of azathioprine: yes/no]. Imaging: imaging of bones and chest (yes/no; kappa = 0.20). Hospitalization: inpatient episodes (yes/no; kappa = 0.64) and number of inpatient days (r = 0.80, P < 0.001). Transport: costs incurred (yes/no; kappa = 0.13) and amount (r = 0.39, P < 0.001).
Conclusion: The use of highly aggregated items to assess health care utilization in RA is supported. Dichotomous assessment (yes/no) was the preferred level of detail for items in the domains covering medication and diagnostic procedures or tests. Metric data is appropriate in 3 areas: number of physician visits, number of inpatient days, and total expenditure on transportation.
Similar articles
-
Is rheumatoid arthritis care more costly when provided by rheumatologists compared with generalists?Arthritis Rheum. 2001 Jul;44(7):1504-14. doi: 10.1002/1529-0131(200107)44:7<1504::AID-ART272>3.0.CO;2-E. Arthritis Rheum. 2001. PMID: 11465700
-
Development and first assessment of a questionnaire for health care utilization and costs for cardiac patients.BMC Health Serv Res. 2008 Sep 19;8:187. doi: 10.1186/1472-6963-8-187. BMC Health Serv Res. 2008. PMID: 18803845 Free PMC article.
-
Utilization and costs of medical services and prescription medications for rheumatoid arthritis among recipients covered by a state Medicaid program: a retrospective, cross-sectional, descriptive, database analysis.Clin Ther. 2007 Nov;29(11):2456-67. doi: 10.1016/j.clinthera.2007.11.009. Clin Ther. 2007. PMID: 18158087
-
An evidence-based assessment of the clinical significance of drug-drug interactions between disease-modifying antirheumatic drugs and non-antirheumatic drugs according to rheumatologists and pharmacists.Clin Ther. 2009 Aug;31(8):1737-46. doi: 10.1016/j.clinthera.2009.08.009. Clin Ther. 2009. PMID: 19808132 Review.
-
Cost assessment instrument in rheumatology: evaluation of applied instrument characteristics.J Rheumatol. 2001 Mar;28(3):662-5. J Rheumatol. 2001. PMID: 11296978 Review.
Cited by
-
Development of a brief, generic, modular resource-use measure (ModRUM): cognitive interviews with patients.BMC Health Serv Res. 2021 Apr 21;21(1):371. doi: 10.1186/s12913-021-06364-w. BMC Health Serv Res. 2021. PMID: 33882905 Free PMC article.
-
Direct costs related to rheumatoid arthritis: the patient perspective.Ann Rheum Dis. 2005 Oct;64(10):1456-61. doi: 10.1136/ard.2004.031880. Epub 2005 Mar 30. Ann Rheum Dis. 2005. PMID: 15800007 Free PMC article.
-
Costs in rheumatology: results and lessons learned from the 'Hannover Costing Study'.Rheumatol Int. 2006 Jun;26(8):704-11. doi: 10.1007/s00296-005-0070-7. Epub 2005 Nov 1. Rheumatol Int. 2006. PMID: 16261384
-
[Conceptual and methodological basics of cost assessments in rheumatology].Z Rheumatol. 2004 Oct;63(5):372-9. doi: 10.1007/s00393-004-0657-5. Z Rheumatol. 2004. PMID: 15517297 German.
-
Productivity loss as a major component of disease-related costs in patients with hypercholesterolemia in Germany.Clin Res Cardiol. 2008 Mar;97(3):152-9. doi: 10.1007/s00392-007-0602-0. Epub 2007 Dec 1. Clin Res Cardiol. 2008. PMID: 18060377 Clinical Trial.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical